Genetico (CGRM, MOEX: GECO) received a patent for Onconetix panel for genetic testing of tumors and selection of target therapy of oncological diseases.
Onconetix — is a panel for search of somatic tumor mutations by NGS (next generation sequencing) method developed by Genetico Center. The test helps oncologists obtain the most complete information about point mutations in the tumor to individually select an efficient therapy of an oncological disease for each patient taking into account genetic features of the tumor.
After the test, a patient receives a conclusion with the description of identified clinically significant mutations as well as a list of target drugs, the response to which is related to the identified mutations. Target drugs enhance the efficiency of cancer therapy as they are aimed at a specific target and affect only certain tumors with identified gene mutations.
According to the International Agency for Research on Cancer (IARC), in 2022 there were 20,000,000 new cancer cases in the world and 9.7 mio. deaths related to oncological diseases. Approximately every fifth person has some oncological disease during life; around 1 in 9 males and 1 in 12 females die because of cancer. According to estimates, the number of oncological patients will grow by 77% and achieve 35 mio. by 2050.
In Russia, NGS tests for oncological patients are included in clinical recommendations and part of them are covered by OMI. Complex NGS-based oncogenetic tests are now paid by patients. At present, Onconetix panel is available at Genetico laboratory and partner clinics. In October 2023, a new branch of Genetico medical genetic center was opened within the Technopark of the Moscow Center of Innovative Technologies in Healthcare (Medtech Moscow) with a consulting physician in oncogenetics.
Genetico Center (CGRM, MOEX: GECO) is a part of Artgen Biotech (MOEX: ABIO), Skolkovo resident, Medtech Technopark resident. The company conducts their business in medical genetics and genetic testing and implements the innovative solutions for diagnostics, prevention and treatment of genetic, oncological and other socially significant and orphan diseases into practical healthcare. In 2023, the company launched a new biotechnological activity — development of gene therapy drugs for treatment of orphan diseases. The trials focus on initial stages of candidate drug development for therapy of ophthalmological diseases, hereditary cardiomyopathies and neurodegenerative diseases.